التفاصيل البيبلوغرافية
| العنوان: |
Method, System, and Computer Program Product For Tracking of Blood Glucose Variability in Diabetes |
| Document Number: |
20110264378 |
| تاريخ النشر: |
October 27, 2011 |
| Appl. No: |
13/131467 |
| Application Filed: |
November 24, 2009 |
| مستخلص: |
An embodiment may be in the field of glycemic analysis and control. More specifically, an embodiment or approach may provide a novel method, system, and computer program for the visual and quantitative tracking of blood glucose variability in diabetes from self-monitoring blood glucose (SMBG) data and/or continuous glucose monitoring (CGM) data. More particularly, an embodiment or aspects thereof may use glucose measurements obtained from self-monitoring data and/or CGM data of an individual or a group of individuals to track and analyze blood glucose variability. |
| Inventors: |
Breton, Marc D. (Charlottesville, VA, US); Kovatchev, Boris P. (Charlottesville, VA, US) |
| Assignees: |
UNIVERSITY OF VIRGINIA PATENT FOUNDATION (Charlottesville, VA, US) |
| Claim: |
1. A system for visually tracking blood glucose variability in diabetes in a subject, said system comprising: an acquisition module acquiring a plurality of blood glucose data; a processor programmed to track blood glucose variability based on said blood glucose data; said tracking providing an area of optimal glucose control in a plane; and said tracking providing areas indicating risk for hyperglycemia and hypoglycemia in said plane. |
| Claim: |
2. The system of claim 1, wherein said plane comprises: a first axis representing the risk for hypoglycemia; and a second axis representing the risk for hyperglycemia. |
| Claim: |
3. The system of claim 1, wherein said plane comprises: a first axis representing the Low Blood Glucose Index (LBGI); and a second axis representing the Low Blood Glucose Index (HBGI). |
| Claim: |
4. The system of claim 1, wherein said plane comprises: a first axis representing the inverse-coded lower percentile; and a second axis representing the upper percentile. |
| Claim: |
5. The system claim 1, wherein said plane comprises at least one of: a first zone representing the optimal control of glucose variability; a second zone representing moderate deviations into hypoglycemia, but good control of hyperglycemia; a third zone representing moderate deviations into hyperglycemia, but good control of hypoglycemia; a fourth zone representing moderate deviations towards both hypoglycemia and hyperglycemia; a fifth zone representing over-correction of hyperglycemia; a sixth zone representing over-correction of hypoglycemia; a seventh zone representing failure to deal with hypoglycemia; an eighth zone representing failure to deal with hyperglycemia; and a ninth zone representing an erroneous control. |
| Claim: |
6. The system of claim 2, wherein said first axis comprises about the inverse-coded 2.5% of a distribution of said blood glucose data and the second axis comprises about the 97.5% of a distribution of said blood glucose data. |
| Claim: |
7. The system of claim 2, wherein said first axis comprises about the 97.5% of a distribution of said blood glucose data and the second axis comprises about the inverse-coded 2.5% of a distribution of said blood glucose data. NOTE: If you reverse the axes, all zones of the next claim would need to be redefined by reversing “first” and “second” axis in the text. This may necessitate a new claim and would be true for all claims defining the grid. |
| Claim: |
8. The system of claim 5, wherein said plane comprises: said first zone further comprises said first axis ranging from about 110-80 mg/dl and said second axis ranging from about 110-200 mg/dl; said second zone further comprises said first axis ranging from about 80-50 mg/dl and said second axis ranging from about 110-200 mg/dl; said third zone further comprises said first axis ranging from about 110-80 mg/dl and said second axis ranging from about 200-400 mg/dl; said fourth zone further comprises said first axis ranging from about 80-50 mg/dl and said second axis ranging from about 200-400 mg/dl; said fifth zone further comprises said first axis ranging from about less than 50 mg/dl and said second axis ranging from about 110-200 mg/dl; said sixth zone further comprises said first axis ranging from about 110-80 mg/dl and said second axis ranging from about greater than 400 mg/dl; said seventh zone further comprises said first axis ranging from about less than 50 mg/dl and said second axis ranging from about 200-400 mg/dl; said eighth zone further comprises said first axis ranging from about 80-50 mg/dl and said second axis ranging from about greater than 400 mg/dl; and said ninth zone further comprises said first axis ranging from about less than 50 mg/dl and said second axis ranging from about greater than 400 mg/dl. |
| Claim: |
9. The system of claim 4, wherein said first axis comprises about the inverse-coded 25% and the second axis comprises about the 75% of said blood glucose data. |
| Claim: |
10. The system of claim 4, wherein said second axis comprises about the inverse-coded 25% and the first axis comprises about the 75% of said blood glucose data. |
| Claim: |
11. The system of claim 5, wherein said hypoglycemia-hyperglycemia plane comprises: said first zone further comprises said first axis ranging from about 110-90 mg/dl and said second axis ranging from about 110-180 mg/dl; said second zone further comprises said first axis ranging from about 90-70 mg/dl and said second axis ranging from about 110-180 mg/dl; said third zone further comprises said first axis ranging from about 110-90 mg/dl and said second axis ranging from about 180-250 mg/dl; said fourth zone further comprises said first axis ranging from about 90-70 mg/dl and said second axis ranging from about 180-250 mg/dl; said fifth zone further comprises said first axis ranging from about less than 70 mg/dl and said second axis ranging from about 110-180 mg/dl; said sixth zone further comprises said first axis ranging from about 110-90 mg/dl and said second axis ranging from about greater than 250 mg/dl; said seventh zone further comprises said first axis ranging from about less than 70 mg/dl and said second axis ranging from about 180-250 mg/dl; said eighth zone further comprises said first axis ranging from about 90-70 mg/dl and said second axis ranging from about greater than 250 mg/dl; and said ninth zone further comprises said first axis ranging from about less than 70 mg/dl and said second axis ranging from about greater than 250 mg/dl. |
| Claim: |
12. The system of claim 3, wherein said first axis comprises a Low Blood Glucose Index (LBGI) of said blood glucose data. |
| Claim: |
13. The system of claim 12, wherein said Low Blood Glucose Index (LBGI) is provided by: [mathematical expression included] where k is the subject and t is the time period. |
| Claim: |
14. The system of claim 3, wherein said second axis comprises a High Blood Glucose Index (HBGI) of said blood glucose data. |
| Claim: |
15. The system of claim 14, wherein said High Blood Glucose Index (HBGI) is provided by: [mathematical expression included] where k is the subject and t is the time period. |
| Claim: |
16. The system of claim 5, wherein said hypoglycemia-hyperglycemia plane comprises: said first zone further comprises said first axis ranging from about less than 2.5 and said second axis ranging from about less than 5; said second zone further comprises said first axis ranging from about 2.5-5 and said second axis ranging from about less than 5; said third zone further comprises said first axis ranging from about less than 2.5 and said second axis ranging from about 5-10; said fourth zone further comprises said first axis ranging from about 2.5-5 and said second axis ranging from about 5-10; said fifth zone further comprises said first axis ranging from about greater than 5 and said second axis ranging from about less than 5; said sixth zone further comprises said first axis ranging from about less than 2.5 and said second axis ranging from about greater than 10; said seventh zone further comprises said first axis ranging from about greater than 5 and said second axis ranging from about 5-10; said eighth zone further comprises said first axis ranging from about 2.5-5 and said second axis ranging from about greater than 10; and said ninth zone further comprises said first axis ranging from about greater than 5 and said second axis ranging from about greater than 10. |
| Claim: |
17. (canceled) |
| Claim: |
18. (canceled) |
| Claim: |
19. The system of claim 1, wherein said tracking determines extreme glucose events. |
| Claim: |
20. The system of claim 1, wherein said tracking determines the extent of glycemic fluctuations over a specified time interval. |
| Claim: |
21. (canceled) |
| Claim: |
22. (canceled) |
| Claim: |
23. (canceled) |
| Claim: |
24. The system of claim 1, wherein said tracking comprises plotting a trajectory of data points from said blood glucose data on a specified time interval. |
| Claim: |
25. (canceled) |
| Claim: |
26. (canceled) |
| Claim: |
27. (canceled) |
| Claim: |
28. The system of claim 1, wherein said blood glucose data is acquired from continuous glucose monitoring (CGM) or self-monitoring blood glucose (SMBG) or both. |
| Claim: |
29. A method for visually tracking blood glucose variability in diabetes in a subject, said method comprising: acquiring a plurality of blood glucose data; tracking blood glucose variability based on said blood glucose data; said tracking providing an area of optimal glucose control in a plane; and said tracking providing areas indicating risk for hyperglycemia and hypoglycemia in said plane. |
| Claim: |
30. The method of claim 29, wherein said plane comprises: a first axis representing the risk for hypoglycemia; and a second axis representing the risk for hyperglycemia. |
| Claim: |
31. The method of claim 29, wherein said plane comprises: a first axis representing the Low Blood Glucose Index (LBGI); and a second axis representing the Low Blood Glucose Index (HBGI). |
| Claim: |
32. The method of claim 29, wherein said plane comprises: a first axis representing the inverse-coded lower percentile; and a second axis representing the upper percentile. |
| Claim: |
33. The method claim 29, wherein said plane comprises at least one of: a first zone representing the optimal control of glucose variability; a second zone representing moderate deviations into hypoglycemia, but good control of hyperglycemia; a third zone representing moderate deviations into hyperglycemia, but good control of hypoglycemia; a fourth zone representing moderate deviations towards both hypoglycemia and hyperglycemia; a fifth zone representing over-correction of hyperglycemia; a sixth zone representing over-correction of hypoglycemia; a seventh zone representing failure to deal with hypoglycemia; an eighth zone representing failure to deal with hyperglycemia; and a ninth zone representing an erroneous control. |
| Claim: |
34. The method of claim 30, wherein said first axis comprises about the inverse-coded 2.5% of a distribution of said blood glucose data and the second axis comprises about the 97.5% of a distribution of said blood glucose data. |
| Claim: |
35. The method of claim 30, wherein said first axis comprises about the 97.5% of a distribution of said blood glucose data and the second axis comprises about the inverse-coded 2.5% of a distribution of said blood glucose data. |
| Claim: |
36. The method of claim 33, wherein said plane comprises: said first zone further comprises said first axis ranging from about 110-80 mg/dl and said second axis ranging from about 110-200 mg/dl; said second zone further comprises said first axis ranging from about 80-50 mg/dl and said second axis ranging from about 110-200 mg/dl; said third zone further comprises said first axis ranging from about 110-80 mg/dl and said second axis ranging from about 200-400 mg/dl; said fourth zone further comprises said first axis ranging from about 80-50 mg/dl and said second axis ranging from about 200-400 mg/dl; said fifth zone further comprises said first axis ranging from about less than 50 mg/dl and said second axis ranging from about 110-200 mg/dl; said sixth zone further comprises said first axis ranging from about 110-80 mg/dl and said second axis ranging from about greater than 400 mg/dl; said seventh zone further comprises said first axis ranging from about less than 50 mg/dl and said second axis ranging from about 200-400 mg/dl; said eighth zone further comprises said first axis ranging from about 80-50 mg/dl and said second axis ranging from about greater than 400 mg/dl; and said ninth zone further comprises said first axis ranging from about less than 50 mg/dl and said second axis ranging from about greater than 400 mg/dl. |
| Claim: |
37. The method of claim 32, wherein said first axis comprises about the inverse-coded 25% and the second axis comprises about the 75% of said blood glucose data. |
| Claim: |
38. The method of claim 32, wherein said second axis comprises about the inverse-coded 25% and the first axis comprises about the 75% of said blood glucose data. |
| Claim: |
39. The method of claim 33, wherein said hypoglycemia-hyperglycemia plane comprises: said first zone further comprises said first axis ranging from about 110-90 mg/dl and said second axis ranging from about 110-180 mg/dl; said second zone further comprises said first axis ranging from about 90-70 mg/dl and said second axis ranging from about 110-180 mg/dl; said third zone further comprises said first axis ranging from about 110-90 mg/dl and said second axis ranging from about 180-250 mg/dl; said fourth zone further comprises said first axis ranging from about 90-70 mg/dl and said second axis ranging from about 180-250 mg/dl; said fifth zone further comprises said first axis ranging from about less than 70 mg/dl and said second axis ranging from about 110-180 mg/dl; said sixth zone further comprises said first axis ranging from about 110-90 mg/dl and said second axis ranging from about greater than 250 mg/dl; said seventh zone further comprises said first axis ranging from about less than 70 mg/dl and said second axis ranging from about 180-250 mg/dl; said eighth zone further comprises said first axis ranging from about 90-70 mg/dl and said second axis ranging from about greater than 250 mg/dl; and said ninth zone further comprises said first axis ranging from about less than 70 mg/dl and said second axis ranging from about greater than 250 mg/dl. |
| Claim: |
40. The method of claim 31, wherein said first axis comprises a Low Blood Glucose Index (LBGI) of said blood glucose data. |
| Claim: |
41. The method of claim 40, wherein said Low Blood Glucose Index (LBGI) is provided by: [mathematical expression included] where k is the subject and t is the time period. |
| Claim: |
42. The method of claim 31, wherein said second axis comprises a High Blood Glucose Index (HBGI) of said blood glucose data. |
| Claim: |
43. The method of claim 42, wherein said High Blood Glucose Index (HBGI) is provided by: [mathematical expression included] where k is the subject and t is the time period. |
| Claim: |
44. The method of claim 33, wherein said hypoglycemia-hyperglycemia plane comprises: said first zone further comprises said first axis ranging from about less than 2.5 and said second axis ranging from about less than 5; said second zone further comprises said first axis ranging from about 2.5-5 and said second axis ranging from about less than 5; said third zone further comprises said first axis ranging from about less than 2.5 and said second axis ranging from about 5-10; said fourth zone further comprises said first axis ranging from about 2.5-5 and said second axis ranging from about 5-10; said fifth zone further comprises said first axis ranging from about greater than 5 and said second axis ranging from about less than 5; said sixth zone further comprises said first axis ranging from about less than 2.5 and said second axis ranging from about greater than 10; said seventh zone further comprises said first axis ranging from about greater than 5 and said second axis ranging from about 5-10; said eighth zone further comprises said first axis ranging from about 2.5-5 and said second axis ranging from about greater than 10; and said ninth zone further comprises said first axis ranging from about greater than 5 and said second axis ranging from about greater than 10. |
| Claim: |
45. (canceled) |
| Claim: |
46. (canceled) |
| Claim: |
47. The method of claim 29, wherein said tracking determines extreme glucose events. |
| Claim: |
48. The method of claim 29, wherein said tracking determines the extent of glycemic fluctuations over a specified time interval. |
| Claim: |
49. (canceled) |
| Claim: |
50. (canceled) |
| Claim: |
51. (canceled) |
| Claim: |
52. The method of claim 29, wherein said tracking comprises plotting a trajectory of data points from said blood glucose data on a specified time interval. |
| Claim: |
53. (canceled) |
| Claim: |
54. (canceled) |
| Claim: |
55. (canceled) |
| Claim: |
56. The method of claim 29, wherein said blood glucose data is acquired from continuous glucose monitoring (CGM) or self-monitoring blood glucose (SMBG) or both. |
| Claim: |
57. (canceled) |
| Claim: |
58. (canceled) |
| Claim: |
59. A computer program product comprising a computer useable medium having a computer program logic for enabling at least one processor in a computer system to track blood glucose variability in diabetes in a subject, or in a group of subjects, said computer program logic comprising: acquiring a plurality of blood glucose data; tracking blood glucose variability based on said blood glucose data; said tracking providing an area of optimal glucose control intended for a plane format: and said tracking providing areas indicating risk for hyperglycemia and hypoglycemia in said plane format. |
| Claim: |
60. The computer program product of claim 59, wherein said plane format is transmitted to an interface. |
| Claim: |
61. (canceled) |
| Claim: |
62. The computer program product of claim 59, wherein said plane format comprises: a first axis representing the risk for hypoglycemia; and a second axis representing the risk for hyperglycemia. |
| Claim: |
63. The computer program product of claim 59, wherein said plane format comprises: a first axis representing the Low Blood Glucose Index (LBGI); and a second axis representing the Low Blood Glucose Index (HBGI). |
| Claim: |
64. The computer program product of claim 59, wherein said plane format comprises: a first axis representing the inverse-coded lower percentile; and a second axis representing the upper percentile. |
| Claim: |
65. The computer program product of claim 59, wherein said plane format comprises at least one of: a first zone representing the optimal control of glucose variability; a second zone representing moderate deviations into hypoglycemia, but good control of hyperglycemia; a third zone representing moderate deviations into hyperglycemia, but good control of hypoglycemia; a fourth zone representing moderate deviations towards both hypoglycemia and hyperglycemia; a fifth zone representing over-correction of hyperglycemia; a sixth zone representing over-correction of hypoglycemia; a seventh zone representing failure to deal with hypoglycemia; an eighth zone representing failure to deal with hyperglycemia; and a ninth zone representing an erroneous control. |
| Claim: |
66. The computer program product of claim 62, wherein said first axis comprises about the inverse-coded 2.5% of a distribution of said blood glucose data and the second axis comprises about the 97.5% of a distribution of said blood glucose data. |
| Claim: |
67. The computer program product of claim 62, wherein said first axis comprises about the 97.5% of a distribution of said blood glucose data and the second axis comprises about the inverse-coded 2.5% of a distribution of said blood glucose data. |
| Claim: |
68. The computer program product of claim 65, wherein said plane format comprises: said first zone further comprises said first axis ranging from about 110-80 mg/dl and said second axis ranging from about 110-200 mg/dl; said second zone further comprises said first axis ranging from about 80-50 mg/dl and said second axis ranging from about 110-200 mg/dl; said third zone further comprises said first axis ranging from about 110-80 mg/dl and said second axis ranging from about 200-400 mg/dl; said fourth zone further comprises said first axis ranging from about 80-50 mg/dl and said second axis ranging from about 200-400 mg/dl; said fifth zone further comprises said first axis ranging from about less than 50 mg/dl and said second axis ranging from about 110-200 mg/dl; said sixth zone further comprises said first axis ranging from about 110-80 mg/dl and said second axis ranging from about greater than 400 mg/dl; said seventh zone further comprises said first axis ranging from about less than 50, mg/dl and said second axis ranging from about 200-400 mg/dl; said eighth zone further comprises said first axis ranging from about 80-50 mg/dl and said second axis ranging from about greater than 400 mg/dl; and said ninth zone further comprises said first axis ranging from about less than 50 mg/dl and said second axis ranging from about greater than 400 mg/dl. |
| Claim: |
69. The computer program product of claim 64, wherein said first axis comprises about the inverse-coded 25% and the second axis comprises about the 75% of said blood glucose data. |
| Claim: |
70. The computer program product of claim 64, wherein said second axis comprises about the inverse-coded 25% and the first axis comprises about the 75% of said blood glucose data. |
| Claim: |
71. The computer program product of claim 64, wherein said hypoglycemia-hyperglycemia plane format comprises: said first zone further comprises said first axis ranging from about 110-90 mg/dl and said second axis ranging from about 110-180 mg/dl; said second zone further comprises said first axis ranging from about 90-70 mg/dl and said second axis ranging from about 110-180 mg/dl; said third zone further comprises said first axis ranging from about 110-90 mg/dl and said second axis ranging from about 180-250 mg/dl; said fourth zone further comprises said first axis ranging from about 90-70 mg/dl and said second axis ranging from about 180-250 mg/dl; said fifth zone further comprises said first axis ranging from about less than 70 mg/dl and said second axis ranging from about 110-180 mg/dl; said sixth zone further comprises said first axis ranging from about 110-90 mg/dl and said second axis ranging from about greater than 250 mg/dl; said seventh zone further comprises said first axis ranging from about less than 70 mg/dl and said second axis ranging from about 180-250 mg/dl; said eighth zone further comprises said first axis ranging from about 90-70 mg/dl and said second axis ranging from about greater than 250 mg/dl; and said ninth zone further comprises said first axis ranging from about less than 70 mg/dl and said second axis ranging from about greater than 250 mg/dl. |
| Claim: |
72. The computer program product of claim 63, wherein said first axis comprises a Low Blood Glucose Index (LBGI) of said blood glucose data. |
| Claim: |
73. The computer program product of claim 72, wherein said Low Blood Glucose Index (LBGI) is provided by: [mathematical expression included] where k is the subject and t is the time period. |
| Claim: |
74. The computer program product of claim 73, wherein said second axis comprises a High Blood Glucose Index (HBGI) of said blood glucose data. |
| Claim: |
75. The computer program product of claim 64, wherein said High Blood Glucose Index (HBGI) is provided by: [mathematical expression included] where k is the subject and t is the time period. |
| Claim: |
76. The computer program product of claim 65, wherein said hypoglycemia-hyperglycemia plane format comprises: said first zone further comprises said first axis ranging from about less than 2.5 and said second axis ranging from about less than 5; said second zone further comprises said first axis ranging from about 2.5-5 and said second axis ranging from about less than 5; said third zone further comprises said first axis ranging from about less than 2.5 and said second axis ranging from about 5-10; said fourth zone further comprises said first axis ranging from about 2.5-5 and said second axis ranging from about 5-10; said fifth zone further comprises said first axis ranging from about greater than 5 and said second axis ranging from about less than 5; said sixth zone further comprises said first axis ranging from about less than 2.5 and said second axis ranging from about greater than 10; said seventh zone further comprises said first axis ranging from about greater than 5 and said second axis ranging from about 5-10; said eighth zone further comprises said first axis ranging from about 2.5-5 and said second axis ranging from about greater than 10; and said ninth zone further comprises said first axis ranging from about greater than 5 and said second axis ranging from about greater than 10. |
| Claim: |
77. (canceled) |
| Claim: |
78. (canceled) |
| Claim: |
79. The computer program product of claim 59, wherein said tracking determines extreme glucose events. |
| Claim: |
80. The computer program product of claim 59, wherein said tracking determines the extent of glycemic fluctuations over a specified time interval. |
| Claim: |
81. (canceled) |
| Claim: |
82. (canceled) |
| Claim: |
83. (canceled) |
| Claim: |
84. The computer program product of claim 59, wherein said tracking comprises plotting a trajectory of data points from said blood glucose data on a specified time interval. |
| Claim: |
85. (canceled) |
| Claim: |
86. (canceled) |
| Claim: |
87. (canceled) |
| Claim: |
88. The computer program product of claim 59, wherein said blood glucose data is acquired from continuous glucose monitoring (CGM) or self-monitoring blood glucose (SMBG) or both. |
| Claim: |
89. (canceled) |
| Claim: |
90. (canceled) |
| Claim: |
91. A system for audibly tracking blood glucose variability in diabetes in a subject, said system comprising: an acquisition module acquiring a plurality of blood glucose data; a processor programmed to track blood glucose variability based on said blood glucose data; said tracking providing a signal for optimal glucose control; and said tracking providing signals indicating risk for hyperglycemia and hypoglycemia. |
| Claim: |
92. A method for audibly tracking blood glucose variability in diabetes in a subject, said method comprising: acquiring a plurality of blood glucose data; tracking blood glucose variability based on said blood glucose data; said tracking providing a signal of optimal glucose control; and said tracking providing signals indicating risk for hyperglycemia and hypoglycemia. |
| Claim: |
93. The system of claim 20, wherein said specified time interval is approximately two or more days. |
| Claim: |
94. The system of claim 20, wherein said specified time interval is approximately a daily basis. |
| Claim: |
95. The system of claim 20, wherein said specified time interval is less than a daily basis. |
| Claim: |
96. The system of claim 20, wherein said specified time interval is approximately half a day. |
| Claim: |
97. The system of claim 20, wherein said specified time interval is approximately two or more hours. |
| Claim: |
98. The system of claim 20, wherein said specified time interval is approximately an hour. |
| Claim: |
99. The system of claim 20, wherein said specified time interval is less than an hour. |
| Claim: |
100. The system of claim 20, wherein said specified time interval is approximately fifteen minutes. |
| Claim: |
101. The method of claim 48, wherein said specified time interval is approximately two or more days. |
| Claim: |
102. The method of claim 48, wherein said specified time interval is approximately a daily basis. |
| Claim: |
103. The method of claim 48, wherein said specified time interval is less than a daily basis. |
| Claim: |
104. The method of claim 48, wherein said specified time interval is approximately half a day. |
| Claim: |
105. The method of claim 48, wherein said specified time interval is approximately two or more hours. |
| Claim: |
106. The method of claim 48, wherein said specified time interval is approximately an hour. |
| Claim: |
107. The method of claim 48, wherein said specified time interval is less than an hour. |
| Claim: |
108. The method of claim 48, wherein said specified time interval is approximately fifteen minutes. |
| Claim: |
109. The computer program product of claim 80, wherein said specified time interval is approximately two or more days. |
| Claim: |
110. The computer program product of claim 80, wherein said specified time interval is approximately a daily basis. |
| Claim: |
111. The computer program product of claim 80, wherein said specified time interval is less than a daily basis. |
| Claim: |
112. The computer program product of claim 80, wherein said specified time interval is approximately half a day. |
| Claim: |
113. The computer program product of claim 80, wherein said specified time interval is approximately two or more hours. |
| Claim: |
114. The computer program product of claim 80, wherein said specified time interval is approximately an hour. |
| Claim: |
115. The computer program product of claim 80, wherein said specified time interval is less than an hour. |
| Claim: |
116. The computer program product of claim 80, wherein said specified time interval is approximately fifteen minutes. |
| Current U.S. Class: |
702/19 |
| Current International Class: |
06; 01 |
| رقم الانضمام: |
edspap.20110264378 |
| قاعدة البيانات: |
USPTO Patent Applications |
